NCT03370744View on ClinicalTrials.gov

Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD

CompletedOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2022

Conditions

Subjective Cognitive DeclinePreclinical Alzheimer's Disease

Interventions

DIAGNOSTIC_TEST

Neuropsychological scale

Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on

Trial Locations (1)

100053

Department of Neurolgy,Xuanwu Hospital of Capital Medical University, Beijing

All Listed Sponsors

lead

XuanwuH 2

OTHER

NCT03370744 - Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD | Biotech Hunter | Biotech Hunter